Bryan C Fuchs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3424614/publications.pdf

Version: 2024-02-01

84 papers	5,064 citations	87723 38 h-index	91712 69 g-index
85 all docs	85 docs citations	85 times ranked	7985 citing authors

#	Article	IF	Citations
1	Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?. Seminars in Cancer Biology, 2005, 15, 254-266.	4.3	608
2	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology, 2014, 59, 1577-1590.	3.6	290
3	Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells. Cancer Research, 2008, 68, 2391-2399.	0.4	287
4	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. Cell Metabolism, 2019, 29, 174-182.e5.	7.2	246
5	HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology, 2019, 156, 2313-2329.e7.	0.6	184
6	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. JAMA - Journal of the American Medical Association, 2008, 299, 53-60.	3.8	183
7	Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. Journal of Hepatology, 2014, 61, S79-S90.	1.8	181
8	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	7.7	172
9	A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma. Gastroenterology, 2011, 141, 141-149.	0.6	133
10	Molecular MRI of collagen to diagnose and stage liver fibrosis. Journal of Hepatology, 2013, 59, 992-998.	1.8	128
11	Cost-Effectiveness of Risk Scoreâ€“Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clinical and Translational Gastroenterology, 2017, 8, e101.	1.3	124
12	Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. Journal of Hepatology, 2020, 73, 896-905.	1.8	119
13	Molecular MR imaging of liver fibrosis: A feasibility study using rat and mouse models. Journal of Hepatology, 2012, 57, 549-555.	1.8	97
14	Molecular Magnetic Resonance Imaging Using a Redox-Active Iron Complex. Journal of the American Chemical Society, 2019, 141, 5916-5925.	6.6	96
15	Stressing Out Over Survival: Glutamine as an Apoptotic Modulator. Journal of Surgical Research, 2006, 131, 26-40.	0.8	91
16	Molecular Magnetic Resonance Imaging of Pulmonary Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 1120-1126.	1.4	89
17	Molecular imaging of fibrosis: recent advances and future directions. Journal of Clinical Investigation, 2019, 129, 24-33.	3.9	86
18	A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome. Clinical Cancer Research, 2008, 14, 3216-3222.	3.2	80

#	Article	IF	Citations
19	The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. Scientific Reports, 2016, 6, 39342.	1.6	77
20	Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology, 2018, 68, 1125-1139.	3.6	74
21	Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structureâ€“Activity Relationships and Lead Candidate Evaluation. Journal of Medicinal Chemistry, 2018, 61, 8811-8824.	2.9	72
22	Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. Science Translational Medicine, 2020, 12, .	5.8	71
23	Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer, 2016, 122, 1216-1227.	2.0	65
24	Epithelial to Mesenchymal Transition is Associated with Shorter Disease-Free Survival in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2014, 21, 3882-3890.	0.7	61
25	Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	60
26	3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. Journal of Hepatology, 2015, 63, 689-696.	1.8	57
27	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut, 2021, 70, 157-169.	6.1	57
28	Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis. JCI Insight, 2017, 2, .	2.3	57
29	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Current Cancer Drug Targets, 2012, 12, 1129-59.	0.8	55
30	T2 relaxation time is related to liver fibrosis severity. Quantitative Imaging in Medicine and Surgery, 2016, 6, 103-114.	1.1	54
31	Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis. Journal of Nuclear Medicine, 2017, 58, 1991-1996.	2.8	50
32	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Letters, 2017, 409, 9-19.	3.2	48
33	Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDPâ€305, a novel farnesoid X receptor agonist. Hepatology Communications, 2018, 2, 821-835.	2.0	46
34	Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. Investigative Radiology, 2019, 54, 697-703.	3.5	45
35	Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model. Hepatology, 2017, 65, 1015-1025.	3.6	43
36	Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a dietâ€induced mouse model of nonalcoholic steatohepatitis. Hepatology Communications, 2018, 2, 529-545.	2.0	43

#	Article	IF	Citations
37	CM-101: Type I Collagenâ€“targeted MR Imaging Probe for Detection of Liver Fibrosis. Radiology, 2018, 287, 581-589.	3.6	43
38	Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. Cancer, 2018, 124, 3084-3104.	2.0	42
39	In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Experimental and Molecular Medicine, 2018, 50, e419-e419.	3.2	37
40	Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis. Cancer Research, 2007, 67, 3295-3300.	0.4	35
41	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials, 2016, 93, 71-82.	5.7	35
42	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med, 2021, 2, 836-850.e10.	2.2	31
43	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Current Pathobiology Reports, 2014, 2, 245-256.	1.6	30
44	Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. Journal of Gastrointestinal Surgery, 2019, 23, 101-111.	0.9	30
45	Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. International Journal of Cancer, 2016, 138, 1494-1505.	2.3	29
46	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports, 2017, 7, 42563.	1.6	29
47	The farnesoid X receptor agonist EDPâ€305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction. FASEB Journal, 2019, 33, 7103-7112.	0.2	29
48	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Clinical Cancer Research, 2020, 26, 5007-5018.	3.2	29
49	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. Journal of Clinical Medicine, 2020, 9, 3817.	1.0	27
50	Serum Angiopoietinâ€2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology, 2019, 69, 729-741.	3.6	26
51	Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer. Annals of Thoracic Surgery, 2015, 100, 414-421.	0.7	25
52	Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prevention Research, 2020, 13, 497-508.	0.7	24
53	STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. Hepatobiliary Surgery and Nutrition, 2016, 5, 201-203.	0.7	23
54	⁶⁸Ga-NODAGA-Indole: An Allysine-Reactive Positron Emission Tomography Probe for Molecular Imaging of Pulmonary Fibrogenesis. Journal of the American Chemical Society, 2019, 141, 5593-5596.	6.6	23

#	Article	IF	Citations
55	The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Molecular and Cellular Oncology, 2017, 4, e1311827.	0.3	22
56	Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. Scientific Reports, 2017, 7, 44867.	1.6	22
57	Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. Radiology, 2020, 296, 67-75.	3.6	22
58	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nature Communications, 2021, 12, 5525.	5.8	21
59	Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model. Cancer Investigation, 2012, 30, 243-250.	0.6	19
60	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. OncoTargets and Therapy, 2013, 6, 1805.	1.0	18
61	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology, 2022, 162, 1210-1225.	0.6	17
62	Genomic risk of hepatitis C-related hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 729-730.	1.8	15
63	Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation. Investigative Radiology, 2020, 55, 209-216.	3.5	15
64	CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. Journal of Surgical Oncology, 2015, 112, 622-628.	0.8	14
65	New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology, 2018, 8, 258.	1.3	14
66	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 317-325.	1.7	12
67	Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. American Journal of Surgery, 2020, 220, 1579-1585.	0.9	12
68	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. PLoS ONE, 2014, 9, e114747.	1.1	11
69	Peroxidasin Deficiency Re-programs Macrophages Toward Pro-fibrolysis Function and Promotes Collagen Resolution in Liver. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1483-1509.	2.3	9
70	Type I Diabetes Affects Skeletal Muscle Glutamine Uptake in a Fiber-Specific Manner. Experimental Biology and Medicine, 2005, 230, 606-611.	1.1	8
71	Collagen-targeted molecular imaging in diffuse liver diseases. Abdominal Radiology, 2020, 45, 3545-3556.	1.0	7
72	Molecular Magnetic Resonance Imaging of Liver Fibrosis and Fibrogenesis Is Not Altered by Inflammation. Investigative Radiology, 2021, 56, 244-251.	3.5	6

#	Article	IF	Citations
73	Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. Molecular Therapy - Oncolytics, 2021, 23, 547-559.	2.0	5
74	Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Scientific Reports, 2021, 11, 6105.	1.6	4
75	Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight, 2022, 7, .	2.3	4
76	THU-093-The calpain inhibitor, BLD-2660, has robust anti-fibrotic activity in a rat model of non-alcoholic steatohepatitis. Journal of Hepatology, 2019, 70, e201-e202.	1.8	3
77	Disease Biomarkers in Gastrointestinal Malignancies. Disease Markers, 2016, 2016, 1-3.	0.6	2
78	Impact of <scp>EGF</scp>,<scp>IL</scp>28B, and <scp>PNPLA</scp>3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clinical Transplantation, 2016, 30, 452-460.	0.8	2
79	Exploring donor demographics effects on hepatocyte yield and viability: Results of whole human liver isolation from one center. Technology, 2019, 07, 1-11.	1.4	2
80	Collagen targeted MRI accurately measures the desmoplastic response to folfirinox treatment in a murine model of pancreatic cancer. Hpb, 2018, 20, S23-S24.	0.1	1
81	Epithelial growth factor receptor inhibition effectively inhibits liver fibrosis and hepatocellular carcinoma. Journal of the American College of Surgeons, 2013, 217, S20.	0.2	0
82	THU-084-A comparative study of anti-Fibrotic therapeutics using aptamer-based quantitative proteomics in a rat model of non-alcoholic steatohepatitis cirrhosis. Journal of Hepatology, 2019, 70, e196-e197.	1.8	0
83	A human liver cell-based system modeling a clinical prognostic liver signature combined with single cell RNA-seq for discovery of novel liver disease therapeutics. Journal of Hepatology, 2020, 73, S28-S29.	1.8	0
84	Abstract 255: Peroxidasin deficiency recruits pro-healing macrophages into the liver and inhibits NAFLD progression to HCC. Cancer Research, 2022, 82, 255-255.	0.4	0